semaglutide france becomes first EU country to reimburse anti-obesity drugs The new generation of blockbuster

Treatment with retatrutide at 8 mg and 12 mg resulted in substantial reductions in liver fat in patients with obesity and metabolic dysfunction-associated steatotic liver disease, according to a presenter at The Liver Meeting

Key Takeaway: Mazdutide demonstrated superiority in combined glycemic control and weight loss

High protein intake, reduced appetite, and gastrointestinal effects demand personalized provider guidance

With a strong foothold in emerging markets and a potential 10x market growth, Ajanta aims to become a leading player in the global GLP-1 market by 2027.

Pharmaceutical giantEli Lilly announced plans Tuesday to invest []